South Korean AI‑driven protein design company Galux signed a research agreement with Boehringer Ingelheim to evaluate AI methods for designing purpose‑specific protein molecules. The collaboration will validate AI frameworks that move beyond prediction to de novo design targeted to precise scientific and translational needs, with initial phases focusing on selected use cases. Galux’s CEO emphasized the partnership’s aim to demonstrate AI’s role in purposeful molecular design and to translate de novo antibody successes into broader therapeutic modalities. Boehringer’s involvement signals large‑pharma interest in integrating AI design into early discovery workflows. The deal fits a pattern of industry partnerships that pair AI discovery startups with established drug developers to accelerate target‑to‑lead timelines and de‑risk preclinical campaigns.